Clinical and immunological measures of low risk and new QRISK3 patients
| Variable* | Low-risk patients with SLE | New QRISK3 group | P values |
| Disease duration (years) | 13.0(8.0,19.0) | 12.0(6.7,15.0) | 0.326 |
| ACR criteria: malar rash | 35(70%) | 14(67%) | 0.785 |
| ACR criteria: discoid rash | 25(50%) | 6(29%) | 0.120 |
| ACR criteria: photosensitivity | 34(68%) | 14(67%) | 1.000 |
| ACR criteria: oral ulcers | 36(72%) | 14(67%) | 0.777 |
| ACR criteria: serositis | 15(30%) | 6(29%) | 1.000 |
| ACR criteria: arthritis | 44(88%) | 14(67%) | 0.047 |
| ACR criteria: renal disorder | 19(38%) | 14(67%) | 0.038 |
| ACR criteria: neurological disorder | 4(8%) | 2(9%) | 1.000 |
| ACR criteria: haematological disorder | 30(60%) | 11(52%) | 0.605 |
| ACR criteria: immunological disorder | 39(78%) | 14(67%) | 0.375 |
| ACR criteria: ANA-positive† | 46(94%) | 18(86%) | 0.352 |
| Anti-dsDNA antibodies† | 15(30%) | 9(43%) | 0.429 |
| Anticardiolipin antibodies† | 4(8%) | 7(33%) | 0.027 |
| Low C3+lowC4 levels† | 5(10%) | 2(9%) | 1.000 |
| Current oral corticosteroids | 19(38%) | 21(100%) | < 0.001 |
| Prednisolone dose (mg/day) | 7.5(5.0,11.3) | 10(5.5,15.0) | 0.304 |
| Current immunosuppressive use | 29(58%) | 13(62%) | 0.582 |
| Current antimalarial use | 36(72%) | 17(81%) | 0.556 |
| SLEDAI-2K (n=58) | 2.5(0.25,4.0) | 3.0(2.0,4.5) | 0.444 |
| BILAG-2004 (n=58) | 1.5(0.25,6.75) | 5.5(0.0,9.3) | 0.542 |
| CD144+EMVs/mL (n=58) | 1.51×106(1.05×106,2.23×106) | 2.45×106(2.05×106,5.56×106) | 0.019 |
| Pulse wave velocity(n=58) | 7.00(6.00,7.70) | 7.60(7.05,9.50) | 0.110 |
| Triglycerides (mg/dL) (n=58) | 0.80(0.60,1.30) | 1.45(1.05,2.53) | 0.022 |
| hsCRP (mg/L) (n=58) | 0.89(0.54,3.01) | 6.70(4.47,8.18) | < 0.001 |
| VCAM-1 (mg/L) (n=58) | 420.76(349.23,492.32) | 502.65(439.72,567.21) | 0.099 |
| BLyS (mg/L) (n=58) | 0.48(0.35,0.61) | 0.61(0.39,0.72) | 0.534 |
*n=71 unless otherwise stated.
†Indicated by laboratory reference range. Data were analysed by Mann-Whitney U and Fisher’s exact tests.
ACR, American College of Rheumatology;BILAG-2004, British Isles Lupus Assessment Group Disease Activity Index;BLyS, B-lymphocyte stimulator;C3, complement component C3;C4, complement component C4;dsDNA, double-stranded DNA;EMV, endothelial microvesicle;hsCRP, high-sensitivity C reactive protein;SLEDAI-2K, SLE Disease Activity Index 2000;VCAM, vascular cell adhesion molecule-1.